These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation. van Vliet EA; Forte G; Holtman L; den Burger JC; Sinjewel A; de Vries HE; Aronica E; Gorter JA Epilepsia; 2012 Jul; 53(7):1254-63. PubMed ID: 22612226 [TBL] [Abstract][Full Text] [Related]
24. Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2⁻/⁻ mice. Bridle KR; Sobbe AL; de Guzman CE; Santrampurwala N; Jaskowski LA; Clouston AD; Campbell CM; Nathan Subramaniam V; Crawford DH Liver Int; 2015 Apr; 35(4):1451-63. PubMed ID: 24517519 [TBL] [Abstract][Full Text] [Related]
25. Performance of a phosphoflow assay to determine phosphorylation of S6 ribosomal protein as a pharmacodynamic read out for mTOR inhibition. Abdel-Kahaar E; Kabakchiev M; Hartmann B; Wieland E; Shipkova M Clin Biochem; 2016 Oct; 49(15):1181-1187. PubMed ID: 27372285 [TBL] [Abstract][Full Text] [Related]
26. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. Curatolo P Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831 [TBL] [Abstract][Full Text] [Related]
27. mTOR signaling inhibition modulates macrophage/microglia-mediated neuroinflammation and secondary injury via regulatory T cells after focal ischemia. Xie L; Sun F; Wang J; Mao X; Xie L; Yang SH; Su DM; Simpkins JW; Greenberg DA; Jin K J Immunol; 2014 Jun; 192(12):6009-19. PubMed ID: 24829408 [TBL] [Abstract][Full Text] [Related]
28. Lipopolysaccharide Induces Chronic Kidney Injury and Fibrosis through Activation of mTOR Signaling in Macrophages. Chen H; Zhu J; Liu Y; Dong Z; Liu H; Liu Y; Zhou X; Liu F; Chen G Am J Nephrol; 2015; 42(4):305-17. PubMed ID: 26517816 [TBL] [Abstract][Full Text] [Related]
29. Cellular and molecular effects of the mTOR inhibitor everolimus. Saran U; Foti M; Dufour JF Clin Sci (Lond); 2015 Nov; 129(10):895-914. PubMed ID: 26330617 [TBL] [Abstract][Full Text] [Related]
30. Pharmacological targeting of mammalian target of rapamycin inhibits ovarian granulosa cell tumor growth. Rico C; Laguë MN; Lefèvre P; Tsoi M; Dodelet-Devillers A; Kumar V; Lapointe E; Paquet M; Nadeau MÈ; Boerboom D Carcinogenesis; 2012 Nov; 33(11):2283-92. PubMed ID: 22871496 [TBL] [Abstract][Full Text] [Related]
31. Rapamycin down-regulates KCC2 expression and increases seizure susceptibility to convulsants in immature rats. Huang X; McMahon J; Yang J; Shin D; Huang Y Neuroscience; 2012 Sep; 219():33-47. PubMed ID: 22613737 [TBL] [Abstract][Full Text] [Related]
32. Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. Zhou X; Wang Y; Metselaar HJ; Janssen HL; Peppelenbosch MP; Pan Q J Hepatol; 2014 Oct; 61(4):746-54. PubMed ID: 24859454 [TBL] [Abstract][Full Text] [Related]
33. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines. Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118 [TBL] [Abstract][Full Text] [Related]
34. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. Aide N; Kinross K; Cullinane C; Roselt P; Waldeck K; Neels O; Dorow D; McArthur G; Hicks RJ J Nucl Med; 2010 Oct; 51(10):1559-64. PubMed ID: 20847160 [TBL] [Abstract][Full Text] [Related]
35. mTOR (Mechanistic Target of Rapamycin) Inhibition Decreases Mechanosignaling, Collagen Accumulation, and Stiffening of the Thoracic Aorta in Elastin-Deficient Mice. Jiao Y; Li G; Li Q; Ali R; Qin L; Li W; Qyang Y; Greif DM; Geirsson A; Humphrey JD; Tellides G Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1657-1666. PubMed ID: 28751568 [TBL] [Abstract][Full Text] [Related]
38. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway. Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281 [TBL] [Abstract][Full Text] [Related]
39. Cerebral dopamine neurotrophic factor protects microglia by combining with AKT and by regulating FoxO1/mTOR signaling during neuroinflammation. Zhang Y; Xiang Y; Wang X; Zhu L; Li H; Wang S; Pan X; Zhao H Biomed Pharmacother; 2019 Jan; 109():2278-2284. PubMed ID: 30551485 [TBL] [Abstract][Full Text] [Related]
40. Everolimus (RAD001) ameliorates vascular cognitive impairment by regulating microglial function via the mTORC1 signaling pathway. Chen L; Zhang Y; Li D; Zhang N; Liu R; Han B; Wei C; Liu H; Xu X; Hao J J Neuroimmunol; 2016 Oct; 299():164-171. PubMed ID: 27725116 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]